(P110) Insulin Efsitora Alfa (Efsitora) Demonstrates Better Overall Health State vs Daily Degludec in Basal Switch Adults with T2D in QWINT-3

This poster reviews the QWINT-3 clinical trial, which included patient-reported outcomes to assess the effect of once-weekly insulin efsitora alfa on treatment satisfaction, burden, and preference in adults with T2D already on basal insulin. Efsitora resulted in a better overall health state, easier management, and reduced treatment burden vs degludec. More participants were “very likely” to incorporate efsitora into their treatment routine.